Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both fir...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Case Rep Oncol
Main Authors: Blasi, Miriam, Kazdal, Daniel, Thomas, Michael, Christopoulos, Petros, Kriegsmann, Mark, Brandt, Regine, Volckmar, Anna-Lena, Kirchner, Martina, Heußel, Claus Peter, Stenzinger, Albrecht, Kuon, Jonas
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2021
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8077408/
https://ncbi.nlm.nih.gov/pubmed/33976623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000513904
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados